BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 26, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/23 cls
Affymax Inc. (NASDAQ:AFFY) Summer Street Carol Werther Price target Buy 2% $24.47
Werther lowered her target to $36 from $49. She expects the company will raise cash prior to a potential launch of Hematide. The synthetic peptide-based erythropoiesis-stimulating agent (ESA) is in Phase III testing to treat anemia in chronic kidney disease (CKD) patients. Werther expects positive data this quarter and an NDA submission in 2H10, with a launch in 2H11.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) UBS Jeff Elliott Price target Buy 3% $56.27
Elliott raised his target to $66 from $56 to reflect increased confidence in the likelihood of a label expansion for Soliris eculizumab to include atypical hemolytic...

Read the full 840 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >